Suggested remit - To appraise the clinical and cost effectiveness of luspatercept within its marketing authirsation for treating beta-thalassaemia
Status
|
Proposed
|
Process |
STA 2018
|
ID number |
1554
|
Provisional Schedule
Committee meeting: 1 |
08 July 2020 |
Expected publication |
16 September 2020 |
Project Team
Email enquiries
Evidence Review Group / Assessment Group |
Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Consultees
Companies sponsors |
Celgene (luspatercept) |
Others |
Department of Health and Social Care |
|
NHS Bexley CCG |
|
NHS England |
|
NHS West London CCG |
|
Welsh Government |
Patient carer groups |
Black Health Agency |
|
Bloodwise |
|
Equalities National Council |
|
Genetic Alliance UK |
|
Muslim Council of Britain |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
|
UK Thalassaemia Society |
Professional groups |
British Blood Transfusion Society |
|
British Society for Bone Marrow Transplantation (BSBMT) |
|
British Committee for Standards in Haematology |
|
British Society for Haematology |
|
NHS Blood & Transplant |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Surgeons |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
UK Clinical Pharmacy Association |
|
UK Forum on Haemoglobin Disorders |
|
UK Haemophilia Centre Doctors’ Organisation |
|
UK National Screening Committee |
Commentators
Assessment group |
Cochrane Haematological Malignancies Group |
|
Genomics England |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |
|
National Primary Care Research & Development Centre |
Associated public health groups |
Public Health England |
|
Public Health Wales |
Comparator companies |
Hospira UK (desferrioxamine) |
|
Novartis Pharmaceuticals (desferrioxamine, deferasirox) |
|
Swedish Orphan Biovitrum (deferiprone) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Hospital Information Services – Jehovah’s Witnesses |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
National Pharmacy Association |
|
NHS Alliance |
|
NHS Confederation |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Date
|
Update
|
25 October 2019
|
Invitation to participate |
24 May 2019 - 24 June 2019
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance